EGFR and non-small cell lung carcinoma: Next, we hypothesized that rare patients with EGFR mutant NSCLC whose tumors harbor co-occurring loss-of-function mutations in ATM (<5% of patients) may exhibit more durable responses to EGFR kinase inhibitors than those whose EGFR mutant tumors lack loss-of-function ATM mutations.